Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma
Emanuel Buehrer, Nina Glassée, Michal Kiciński, Oliver John Kennedy, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma. , DOI: https://doi.org/10.1016/j.ejcskn.2025.100727.
Article320 days agoLBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
G.V. Long, C.U. Blank, R. Amaria, Tina J. Hieken, Shahneen Sandhu, M.J. Barros, T.C.C. Mitchell, Zeynep Eroglu, Igor Samoylenko, P. Rutkowski, D.B. Johnson, I. Pires da Silva, Kyle A. Perry, H.A. Tawbi, Matthew S. Block, P.A. Ascierto, Eric Burton, Alexander C.J. van Akkooi, Richard A. Scolyer, A.M. Menzies (2024). LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2282.
Article320 days agoReal-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, Itske Fraterman, Anke Kuijpers, Winan J. van Houdt, Sofie Wilgenhof, Aparna D. Rao, Shahneen Sandhu, Rebecca Lee, Hanna Eriksson, Marieke van Leeuwen, Kelly de Ligt, Alexander C.J. van Akkooi, Lonneke V. van de Poll‐Franse (2024). Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy. , 200, DOI: https://doi.org/10.1016/j.ejca.2024.113601.
Article320 days agoAdjuvant therapy for stage II melanoma: the need for further studies
Rebecca Lee, Mario Mandalà, Georgina V. Long, Alexander M.M. Eggermont, Alexander C.J. van Akkooi, Shahneen Sandhu, Claus Garbe, Paul Lorigan (2023). Adjuvant therapy for stage II melanoma: the need for further studies. , 189, DOI: https://doi.org/10.1016/j.ejca.2023.05.003.
Article320 days agoPrognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassée, Michal Kiciński, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Emanuel Buhrer, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Mario Mandalà, Paul Lorigan, Sara Valpione (2024). Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 201, DOI: https://doi.org/10.1016/j.ejca.2024.113585.
Article320 days ago